Fast platelet recovery is associated with remission in primary immune thrombocytopenia

Basit Öğe Kaydı
dc.contributor.authorHatip, Fatma Gür
dc.contributor.authorÖzbalcı, Demircan
dc.contributor.authorAlanoğlu, Emine Güçhan
dc.contributor.authorHatip, Ahmet Yunus
dc.date.accessioned2024-11-07T13:16:10Z
dc.date.available2024-11-07T13:16:10Z
dc.date.issued2023
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractObjectives: We aimed to reveal predictors of response and response duration to steroid therapy in first line of treatment in immune thrombocytopenia (ITP). Methods: Fifty patients, who were diagnosed with ITP in hematology department of Suleyman Demirel University Hospital between 2005-2019, who had sufficient clinical and laboratory data, followed up for at least one year and received corticosteroid treatment in first line, were evaluated retrospectively for treatment response time, remission, prognosis on their first line treatment. The patients who maintained remission for more than 12 months was defined as group 1 and those who did not achieve remission or relapsed in less than 12 months were defined as group 2. Results: Twenty-two (44%) patients responded in first 3 days of the treatment, 16 (32%) patients in 4 to 7 days and 4 (8%) patients responded in more than 7 days. Eighty-four percent (n = 42) of these patients had complete response to corticosteroid treatment. When the remission maintenances were examined, it was observed that 22 (44%) patients were in remission for more than 12 months, 20 (40%) patients were in remission with treatment but relapsed before 12 months and 8 (16%) patients did not respond to corticosteroid treatment. When the response time to treatment in patients with or without remission was compared, remission was significantly lower in those who responded late to treatment (p = 0.01). When the response rates to corticosteroid treatment of patients in group 1 and 2 were evaluated, it was found that the response time to treatment was not related to the maintenance of remission (p = 0.267). Conclusions: Faster response time to treatment produced higher remission rates but, we could not find any relationship between response time to treatment and duration of remission.
dc.identifier.doi10.18621/eurj.1170790
dc.identifier.endpage1349
dc.identifier.issn2149-3189
dc.identifier.issue6
dc.identifier.startpage1343
dc.identifier.trdizinid1207246
dc.identifier.urihttps://doi.org/10.18621/eurj.1170790
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1207246
dc.identifier.urihttps://hdl.handle.net/11480/12122
dc.identifier.volume9
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofThe European Research Journal
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241107
dc.subjectTıbbi Araştırmalar Deneysel
dc.subjectHalk ve Çevre Sağlığı
dc.subjectPatoloji
dc.subjectKlinik Nöroloji
dc.subjectMikrobiyoloji
dc.subjectHematoloji
dc.subjectSağlık Bilimleri ve Hizmetleri
dc.subjectTıbbi Laboratuar Teknolojisi
dc.subjectPrognosis
dc.subjectremission
dc.subjectImmune thrombocytopenia
dc.subjectfast recovery
dc.titleFast platelet recovery is associated with remission in primary immune thrombocytopenia
dc.typeArticle

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu